FDA WARNING LETTER RESPONSE

RESPONSE COVER LETTER

Date: [__/__/____]

Via Electronic Submission and/or Certified Mail

Food and Drug Administration
[________________________________]
[________________________________]
[________________________________]

Re: Response to Warning Letter
Warning Letter Number: [________________________________]
Date of Warning Letter: [__/__/____]
Firm Name: [________________________________]
FEI Number: [________________________________]

Dear [________________________________]:

This letter constitutes [________________________________] ("Company") formal response to the Warning Letter dated [__/__/____] (the "Warning Letter"), which was received by the Company on [__/__/____]. We take the concerns raised in the Warning Letter very seriously and are committed to achieving full compliance with FDA regulations.

The Company appreciates the opportunity to respond and provide detailed information regarding the corrective actions we have implemented or are implementing to address each observation cited in the Warning Letter.

SECTION 1: EXECUTIVE SUMMARY

1.1 Company Background

Company Name: [________________________________]

Address: [________________________________]

Type of Facility: [________________________________]

Products Manufactured/Distributed: [________________________________]

FDA Registration Number: [________________________________]

DUNS Number: [________________________________]

1.2 Summary of Corrective Actions

SECTION 2: DETAILED RESPONSE TO CITATIONS

Citation 1

FDA Citation: [________________________________]

Regulatory Reference: [________________________________]

Company Response:

Root Cause Analysis

[________________________________]

Immediate Corrective Actions Taken

☐ [________________________________]
☐ [________________________________]
☐ [________________________________]

Date(s) Completed: [__/__/____]

Long-Term Preventive Actions (CAPA)

Documentation Attached

☐ Updated SOP(s): [________________________________]
☐ Training Records: [________________________________]
☐ Batch Records: [________________________________]
☐ Test Results: [________________________________]
☐ Other: [________________________________]

Citation 2

FDA Citation: [________________________________]

Regulatory Reference: [________________________________]

Company Response:

Root Cause Analysis

[________________________________]

Immediate Corrective Actions Taken

☐ [________________________________]
☐ [________________________________]
☐ [________________________________]

Date(s) Completed: [__/__/____]

Long-Term Preventive Actions (CAPA)

Documentation Attached

☐ Updated SOP(s): [________________________________]
☐ Training Records: [________________________________]
☐ Batch Records: [________________________________]
☐ Test Results: [________________________________]
☐ Other: [________________________________]

Citation 3

FDA Citation: [________________________________]

Regulatory Reference: [________________________________]

Company Response:

Root Cause Analysis

[________________________________]

Immediate Corrective Actions Taken

☐ [________________________________]
☐ [________________________________]
☐ [________________________________]

Date(s) Completed: [__/__/____]

Long-Term Preventive Actions (CAPA)

Documentation Attached

☐ Updated SOP(s): [________________________________]
☐ Training Records: [________________________________]
☐ Batch Records: [________________________________]
☐ Test Results: [________________________________]
☐ Other: [________________________________]

SECTION 3: SYSTEMIC IMPROVEMENTS

3.1 Quality Management System Enhancements

☐ Quality Manual updated
☐ CAPA procedures revised
☐ Internal audit program enhanced
☐ Management review procedures improved
☐ Document control system upgraded
☐ Training program expanded

Description of Improvements:

[________________________________]

3.2 Personnel and Training

3.3 Third-Party Consultant Engagement (if applicable)

☐ Yes, consultant engaged
☐ No consultant engaged

Consultant Name: [________________________________]

Scope of Engagement: [________________________________]

Engagement Period: [__/__/____] to [__/__/____]

SECTION 4: COMMITMENTS AND TIMELINE

4.1 Completion Timeline

4.2 Ongoing Monitoring Commitments

☐ Monthly internal audits for [____] months
☐ Quarterly management reviews
☐ Annual third-party audit
☐ Periodic progress reports to FDA
☐ Other: [________________________________]

SECTION 5: CONTACT INFORMATION

Primary Contact for FDA Communications:

Name: [________________________________]

Title: [________________________________]

Phone: [________________________________]

Email: [________________________________]

Address: [________________________________]

SECTION 6: CERTIFICATION

We certify that the information provided in this response is accurate and complete to the best of our knowledge. We are committed to maintaining full compliance with FDA regulations and welcome any follow-up inspection or communication.

Signature: ________________________________________

Printed Name: [________________________________]

Title: [________________________________]

Date: [__/__/____]

ATTACHMENTS CHECKLIST

☐ Attachment A: Corrective Action Documentation
☐ Attachment B: Updated Standard Operating Procedures
☐ Attachment C: Training Records and Certifications
☐ Attachment D: Test Results and Validation Reports
☐ Attachment E: Organizational Chart
☐ Attachment F: Timeline/Gantt Chart
☐ Attachment G: Third-Party Assessment Report
☐ Attachment H: [________________________________]
☐ Attachment I: [________________________________]

IMPORTANT NOTES

Response Timeline

• FDA requires a written response within 15 working days of receipt of a Warning Letter
• Request for extension must be made before the deadline expires
• Extensions may be granted for complex matters requiring additional investigation

Response Submission

• Submit response to the FDA District Office identified in the Warning Letter
• Keep copies of all correspondence and documentation
• Consider submitting via electronic submission AND certified mail with return receipt

Consequences of Non-Response

• Failure to respond may result in regulatory action without further notice
• Potential enforcement actions include:
• Seizure of products
• Injunction proceedings
• Civil money penalties
• Criminal prosecution
• Import detention

Best Practices

• Address each citation individually and specifically
• Provide objective evidence of corrective actions
• Include realistic timelines for completion
• Assign specific responsibility for each action item
• Maintain detailed records of all corrective actions

SOURCES AND REFERENCES

• FDA Regulatory Procedures Manual Chapter 4: Advisory Actions
• 21 CFR Part 7 - Enforcement Policy
• FDA Warning Letters Database: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters

This template is provided for informational purposes only. Each Warning Letter response must be tailored to the specific citations and circumstances involved. Legal counsel experienced in FDA regulatory matters should review any response before submission.